{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:45:24Z","timestamp":1791762324419,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["232684, 200734"],"award-info":[{"award-number":["232684, 200734"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r Strategisk Forskning","doi-asserted-by":"publisher","award":["2-1329\/2024"],"award-info":[{"award-number":["2-1329\/2024"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-03427, 2020-06121, 2019-01502, 2021-06122"],"award-info":[{"award-number":["2020-03427, 2020-06121, 2019-01502, 2021-06122"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pulmonary nodules are highly prevalent in adult human populations, with a substantial proportion representing dormant cancerous lesions. We hypothesized that these pulmonary dormant cancers debilitate in growth owing to the lack of an angiogenic switch in tumors. In this study, we comprehensively investigated the hypothesis that specific pathological triggers can activate this angiogenic switch utilizing severe acute respiratory coronavirus 2 (SARS-CoV-2) infection-induced hypoxia as a primary physiological stimulus. Our findings provide compelling experimental evidence demonstrating that SARS-CoV-2 infection induces profound pulmonary hypoxia and severe tissue inflammation in animal models. This microenvironmental disruption markedly upregulates the expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR2) within lung tissues. The resulting hyperactivation of the downstream VEGF-VEGFR2 signaling pathway effectively drives robust pulmonary neovascularization, a phenomenon frequently documented in clinical observations of COVID-19 patients. Furthermore, employing an established experimental tumor model, we demonstrated that SARS-CoV-2 infection directly accelerates tumor outgrowth via this specific VEGF angiogenesis-dependent cascade. Crucially, the targeted administration of a neutralizing antibody to block VEGF significantly suppressed tumor progression and outgrowth in SARS-CoV-2-infected, tumor-bearing animals. Our data show that the COVID-19-induced hypoxia-VEGF-angiogenesis axis serves as one of the mechanisms for initiating tumor outgrowth in pulmonary tissues.<\/jats:p>","DOI":"10.1038\/s41392-026-02952-6","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:01:56Z","timestamp":1791759716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 triggers pulmonary tumor outgrowth through hypoxia- and inflammation-induced VEGF-dependent angiogenesis"],"prefix":"10.1038","volume":"11","author":[{"given":"Xu","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-8092","authenticated-orcid":false,"given":"Xiaoting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Holgersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-6473","authenticated-orcid":false,"given":"Xiaolu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald M.","family":"McInerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Adner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-2546","authenticated-orcid":false,"given":"Yuguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-0065","authenticated-orcid":false,"given":"Yihai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2952_CR1","first-page":"7","volume":"12","author":"M Tufail","year":"2025","unstructured":"Tufail, M., Jiang, C. H. & Li, N. Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence. Mil. Med Res. 12, 7 (2025).","journal-title":"Mil. Med Res."},{"key":"2952_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834\u2013846 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"2952_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14740\/wjon1419","volume":"13","author":"V Balayan","year":"2022","unstructured":"Balayan, V. & Guddati, A. K. Tumor Dormancy: Biologic and Therapeutic Implications. World J. Oncol. 13, 8\u201319 (2022).","journal-title":"World J. Oncol."},{"key":"2952_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41416-023-02401-z","volume":"129","author":"WA Weston","year":"2023","unstructured":"Weston, W. A. & Barr, A. R. A cell cycle centric view of tumour dormancy. Br. J. Cancer 129, 1535\u20131545 (2023).","journal-title":"Br. J. Cancer"},{"key":"2952_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molonc.2016.09.009","volume":"11","author":"RR Gomis","year":"2017","unstructured":"Gomis, R. R. & Gawrzak, S. Tumor cell dormancy. Mol. Oncol. 11, 62\u201378 (2017).","journal-title":"Mol. Oncol."},{"key":"2952_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1096\/fj.01-0813com","volume":"16","author":"T Udagawa","year":"2002","unstructured":"Udagawa, T., Fernandez, A., Achilles, E. G., Folkman, J. & D\u2019Amato, R. J. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. 16, 1361\u20131370 (2002).","journal-title":"FASEB J."},{"key":"2952_CR7","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/CM9.0000000000003231","volume":"137","author":"Z Guo","year":"2024","unstructured":"Guo, Z. et al. Tumor angiogenesis and anti-angiogenic therapy. Chin. Med J. (Engl.) 137, 2043\u20132051 (2024).","journal-title":"Chin. Med J. (Engl.)"},{"key":"2952_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/jcm2030136","volume":"2","author":"M Osisami","year":"2013","unstructured":"Osisami, M. & Keller, E. T. Mechanisms of metastatic tumor dormancy. J. Clin. Med 2, 136\u2013150 (2013).","journal-title":"J. Clin. Med"},{"key":"2952_CR9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4143\/crt.2023.468","volume":"55","author":"HY Min","year":"2023","unstructured":"Min, H. Y. & Lee, H. Y. Cellular dormancy in cancer: mechanisms and potential targeting strategies. Cancer Res Treat. 55, 720\u2013736 (2023).","journal-title":"Cancer Res Treat."},{"key":"2952_CR10","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-15-1370","volume":"75","author":"AC Yeh","year":"2015","unstructured":"Yeh, A. C. & Ramaswamy, S. Mechanisms of cancer cell dormancy\u2013another hallmark of cancer? Cancer Res. 75, 5014\u20135022 (2015).","journal-title":"Cancer Res."},{"key":"2952_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc2933","volume":"10","author":"PE Goss","year":"2010","unstructured":"Goss, P. E. & Chambers, A. F. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10, 871\u2013877 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"2952_CR12","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.4161\/cc.5.16.3018","volume":"5","author":"GN Naumov","year":"2006","unstructured":"Naumov, G. N., Akslen, L. A. & Folkman, J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779\u20131787 (2006).","journal-title":"Cell Cycle"},{"key":"2952_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nm0696-689","volume":"2","author":"MS O\u2019Reilly","year":"1996","unstructured":"O\u2019Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689\u2013692 (1996).","journal-title":"Nat. Med."},{"key":"2952_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","volume":"79","author":"MS O\u2019Reilly","year":"1994","unstructured":"O\u2019Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315\u2013328 (1994).","journal-title":"Cell"},{"key":"2952_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nm0295-149","volume":"1","author":"L Holmgren","year":"1995","unstructured":"Holmgren, L., O\u2019Reilly, M. S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149\u2013153 (1995).","journal-title":"Nat. Med."},{"key":"2952_CR16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1172\/JCI1558","volume":"101","author":"Y Cao","year":"1998","unstructured":"Cao, Y. et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J. Clin. Invest. 101, 1055\u20131063 (1998).","journal-title":"J. Clin. Invest."},{"key":"2952_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","volume":"3","author":"G Bergers","year":"2003","unstructured":"Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401\u2013410 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"2952_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao, Y., Langer, R. & Ferrara, N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat. Rev. Drug Discov. 22, 476\u2013495 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2952_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med 9, 669\u2013676 (2003).","journal-title":"Nat. Med"},{"key":"2952_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 176, 1248\u20131264 (2019).","journal-title":"Cell"},{"key":"2952_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang, Y. & Cao, Y. The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 86, 251\u2013261 (2022).","journal-title":"Semin Cancer Biol."},{"key":"2952_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nrendo.2014.114","volume":"10","author":"Y Cao","year":"2014","unstructured":"Cao, Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat. Rev. Endocrinol. 10, 530\u2013539 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2952_CR23","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I. & Pourgholami, M. H. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur. J. Pharm. 949, 175586 (2023).","journal-title":"Eur. J. Pharm."},{"key":"2952_CR24","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1016\/j.cell.2021.07.023","volume":"184","author":"CGK Ziegler","year":"2021","unstructured":"Ziegler, C. G. K. et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell 184, 4713\u20134733.e4722 (2021).","journal-title":"Cell"},{"key":"2952_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2952_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103812","volume":"75","author":"T Won","year":"2022","unstructured":"Won, T. et al. Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs. EBioMedicine 75, 103812 (2022).","journal-title":"EBioMedicine"},{"key":"2952_CR27","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jhep.2024.06.014","volume":"81","author":"M Cadamuro","year":"2024","unstructured":"Cadamuro, M. et al. Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19. J. Hepatol. 81, 872\u2013885 (2024).","journal-title":"J. Hepatol."},{"key":"2952_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/28867","volume":"394","author":"P Carmeliet","year":"1998","unstructured":"Carmeliet, P. et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485\u2013490 (1998).","journal-title":"Nature"},{"key":"2952_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"2952_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721\u2013732 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"2952_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21085-8","volume":"12","author":"J Pang","year":"2021","unstructured":"Pang, J. et al. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat. Commun. 12, 814 (2021).","journal-title":"Nat. Commun."},{"key":"2952_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20210051","volume":"1","author":"Y Cao","year":"2021","unstructured":"Cao, Y. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients. Exploration (Beijing) 1, 20210051 (2021).","journal-title":"Exploration (Beijing)"},{"key":"2952_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10147-025-02695-4","volume":"30","author":"H Yamamoto","year":"2025","unstructured":"Yamamoto, H., Shirasawa, M. & Naoki, K. Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975-2022 with insights on the impact of COVID-19. Int J. Clin. Oncol. 30, 199\u2013209 (2025).","journal-title":"Int J. Clin. Oncol."},{"key":"2952_CR34","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.chest.2023.01.008","volume":"163","author":"S Gysling","year":"2023","unstructured":"Gysling, S. et al. The Impact of COVID-19 on lung cancer incidence in England: analysis of the National Lung Cancer Audit 2019 and 2020 rapid cancer registration datasets. Chest 163, 1599\u20131607 (2023).","journal-title":"Chest"},{"key":"2952_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1370862","volume":"14","author":"NL Barclay","year":"2024","unstructured":"Barclay, N. L. et al. The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study. Front Oncol. 14, 1370862 (2024).","journal-title":"Front Oncol."},{"key":"2952_CR36","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1016\/j.cell.2026.02.013","volume":"189","author":"W Qian","year":"2026","unstructured":"Qian, W. et al. Respiratory viral infections prime accelerated lung cancer growth. Cell 189, 2845\u20132856.e2820 (2026).","journal-title":"Cell"},{"key":"2952_CR37","doi-asserted-by":"publisher","first-page":"1534074","DOI":"10.3389\/fonc.2025.1534074","volume":"15","author":"Z He","year":"2025","unstructured":"He, Z., Liu, K., Wu, L., Wei, Q. & Shen, Q. Analysis of screen-detected pulmonary nodules before and after the novel coronavirus epidemic: a multicenter retrospective cohort study. Front Oncol. 15, 1534074 (2025).","journal-title":"Front Oncol."},{"key":"2952_CR38","doi-asserted-by":"publisher","first-page":"102500","DOI":"10.1016\/j.eclinm.2024.102500","volume":"69","author":"M Meng","year":"2024","unstructured":"Meng, M. et al. Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study. EClinicalMedicine 69, 102500 (2024).","journal-title":"EClinicalMedicine"},{"key":"2952_CR39","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s42255-022-00697-4","volume":"4","author":"X Jing","year":"2022","unstructured":"Jing, X. et al. COVID-19 instigates adipose browning and atrophy through VEGF in small mammals. Nat. Metab. 4, 1674\u20131683 (2022).","journal-title":"Nat. Metab."},{"key":"2952_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target Ther. 5, 33 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2952_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216899","volume":"591","author":"R Liu","year":"2024","unstructured":"Liu, R. et al. Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces. Cancer Lett. 591, 216899 (2024).","journal-title":"Cancer Lett."},{"key":"2952_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795\u2013803 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"2952_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303740120","volume":"120","author":"K Hosaka","year":"2023","unstructured":"Hosaka, K. et al. KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas. Proc. Natl. Acad. Sci. USA 120, e2303740120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2952_CR44","doi-asserted-by":"publisher","first-page":"12018","DOI":"10.1073\/pnas.1301331110","volume":"110","author":"Y Yang","year":"2013","unstructured":"Yang, Y. et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc. Natl. Acad. Sci. USA 110, 12018\u201312023 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2952_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00384-025-04806-z","volume":"40","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study. Int J. Colorectal Dis. 40, 20 (2025).","journal-title":"Int J. Colorectal Dis."},{"key":"2952_CR46","doi-asserted-by":"publisher","first-page":"14389","DOI":"10.1073\/pnas.95.24.14389","volume":"95","author":"Y Cao","year":"1998","unstructured":"Cao, Y. et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 95, 14389\u201314394 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2952_CR47","doi-asserted-by":"publisher","first-page":"1209-+","DOI":"10.1126\/science.abc8511","volume":"369","author":"D Mathew","year":"2020","unstructured":"Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, 1209-+ (2020).","journal-title":"Science"},{"key":"2952_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58\u201362 (2005).","journal-title":"Science"},{"key":"2952_CR49","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med"},{"key":"2952_CR50","doi-asserted-by":"publisher","first-page":"E6447","DOI":"10.1073\/pnas.1612290113","volume":"113","author":"TJ Bartosh","year":"2016","unstructured":"Bartosh, T. J., Ullah, M., Zeitouni, S., Beaver, J. & Prockop, D. J. Cancer cells enter dormancy after cannibalizing mesenchymal stem\/stromal cells (MSCs). P Natl. Acad. Sci. USA 113, E6447\u2013E6456 (2016).","journal-title":"P Natl. Acad. Sci. USA"},{"key":"2952_CR51","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/CM9.0000000000003002","volume":"137","author":"YH Cao","year":"2024","unstructured":"Cao, Y. H. Angiogenesis in diseases: A half-century excursion from the initial therapeutic concept to current clinical benefits. Chin. Med J. -Peking. 137, 636\u2013637 (2024).","journal-title":"Chin. Med J. -Peking."},{"key":"2952_CR52","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10456-024-09913-z","volume":"27","author":"F Yang","year":"2024","unstructured":"Yang, F., Lee, G. & Fan, Y. Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism. Angiogenesis 27, 333\u2013349 (2024).","journal-title":"Angiogenesis"},{"key":"2952_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1101\/gad.14.1.34","volume":"14","author":"R Ravi","year":"2000","unstructured":"Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34\u201344 (2000).","journal-title":"Genes Dev."},{"key":"2952_CR54","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu, Z. L., Chen, H. H., Zheng, L. L., Sun, L. P. & Shi, L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Sig. Transduct. Target Ther. 8, 198 (2023).","journal-title":"Sig. Transduct. Target Ther."},{"key":"2952_CR55","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson, G. C., Kerbel, R., Ellis, L. M. & Harris, A. L. Antiangiogenic therapy in oncology: current status and future directions. Lancet 388, 518\u2013529 (2016).","journal-title":"Lancet"},{"key":"2952_CR56","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41401-022-00998-0","volume":"44","author":"SW Xu","year":"2023","unstructured":"Xu, S. W., Ilyas, I. & Weng, J. P. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharm. Sin. 44, 695\u2013709 (2023).","journal-title":"Acta Pharm. Sin."},{"key":"2952_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct. Target Ther. 8, 70 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2952_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2023.121715","volume":"329","author":"SM Ji","year":"2023","unstructured":"Ji, S. M. et al. Mild exposure to fine particulate matter promotes angiogenesis in non-small cell lung carcinoma. Environ. Pollut. 329, 121715 (2023).","journal-title":"Environ. Pollut."},{"key":"2952_CR59","doi-asserted-by":"crossref","unstructured":"Camell, C. D. et al. Senolytics reduce coronavirus-related mortality in old mice. Science 373, eabe4832 (2021).","DOI":"10.1093\/geroni\/igab046.951"},{"key":"2952_CR60","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","volume":"10","author":"C Lee","year":"2025","unstructured":"Lee, C. et al. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct. Target Ther. 10, 170 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2952_CR61","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Yang, H., Chon, H. J. & Kim, C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 52, 1475\u20131485 (2020).","journal-title":"Exp. Mol. Med."},{"key":"2952_CR62","doi-asserted-by":"publisher","first-page":"E990","DOI":"10.1073\/pnas.1615758114","volume":"114","author":"K Hoppe-Seyler","year":"2017","unstructured":"Hoppe-Seyler, K. et al. Induction of dormancy in hypoxic human papillomavirus-positive cancer cells. Proc. Natl. Acad. Sci. USA 114, E990\u2013E998 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2952_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100450","volume":"2","author":"DJ Sheward","year":"2021","unstructured":"Sheward, D. J. et al. Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. Cell Rep. Med. 2, 100450 (2021).","journal-title":"Cell Rep. Med."},{"key":"2952_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1400244","volume":"1","author":"H Iwamoto","year":"2015","unstructured":"Iwamoto, H. et al. PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors. Sci. Adv. 1, e1400244 (2015).","journal-title":"Sci. Adv."},{"key":"2952_CR65","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1073\/pnas.0911661107","volume":"107","author":"R Cao","year":"2010","unstructured":"Cao, R. et al. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc. Natl. Acad. Sci. USA 107, 856\u2013861 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2952_CR66","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1096\/fasebj.13.15.2195","volume":"13","author":"R Cao","year":"1999","unstructured":"Cao, R., Farnebo, J., Kurimoto, M. & Cao, Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 13, 2195\u20132202 (1999).","journal-title":"FASEB J."},{"key":"2952_CR67","volume":"10","author":"J Wu","year":"2023","unstructured":"Wu, J. et al. Disruption of the clock component bmal1 in mice promotes cancer metastasis through the PAI-1-TGF-beta-myoCAF-dependent mechanism. Adv. Sci. (Weinh.) 10, e2301505 (2023).","journal-title":"Adv. Sci. (Weinh.)"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02952-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02952-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02952-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:01:58Z","timestamp":1791759718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02952-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02952-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yihai Cao is an editorial board member of Signal Transduction and Targeted Therapy, but he has not been involved in the process of handling the manuscript. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"441"}}